Alcresta Therapeutics Announces Publication of Real-World Evidence Showing Improvements in Growth for Children Ages 1 to 5 Years Old With Use of RELiZORB®

Clinical data published in Nutrients highlights significant improvements in weight and body mass index (BMI) z-scores with use of RELiZORB WALTHAM, Mass., Jan. 23, 2026 /PRNewswire/ -- Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and...